Piramal Pharma Ltd
NSE:PPLPHARMA
Piramal Pharma Ltd
Interest Income Expense
Piramal Pharma Ltd
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Piramal Pharma Ltd
NSE:PPLPHARMA
|
Interest Income Expense
₹1.1B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Interest Income Expense
-₹2.6B
|
CAGR 3-Years
-151%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Interest Income Expense
-₹655.8m
|
CAGR 3-Years
17%
|
CAGR 5-Years
19%
|
CAGR 10-Years
8%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Interest Income Expense
-₹3.2B
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
4%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Interest Income Expense
-₹2.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
10%
|
CAGR 10-Years
-6%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Interest Income Expense
₹1.7B
|
CAGR 3-Years
21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Piramal Pharma Ltd
Glance View
Piramal Pharma Ltd. has embarked on a remarkable journey that reflects the dynamic world of pharmaceuticals and healthcare. Emerging from the rich tapestry of the Piramal Group's diverse business ventures, it has carved out a distinctive place for itself in the global pharmaceutical landscape. The company primarily navigates through three major streams: Contract Development and Manufacturing Organization (CDMO), Critical Care, and Consumer Products. Its CDMO division is the backbone, providing end-to-end solutions spanning the entire drug lifecycle, from development through to commercial manufacturing. By offering tailored solutions to pharmaceutical companies globally, Piramal Pharma not only strengthens its revenue streams but also builds lasting partnerships with some of the world’s leading pharmaceutical innovators. Beyond the realm of CDMO, Piramal Pharma's Critical Care segment specializes in catering to the acute care sector, dealing especially with inhalation anesthesia and pain management solutions. This division operates globally, emphasizing a diligent supply chain that ensures these life-sustaining products reach hospitals and clinics around the world. Meanwhile, its Consumer Products business makes a concerted effort to touch lives in a different manner—through over-the-counter health solutions that meet everyday health concerns of countless individuals. Operating at this unique intersection where science meets humanity, Piramal Pharma not only thrives through product sales but also invests heavily in R&D, seeking out innovative ways to address evolving market needs and inch its way forward in the competitive pharmaceutical arena.
See Also
What is Piramal Pharma Ltd's Interest Income Expense?
Interest Income Expense
1.1B
INR
Based on the financial report for Mar 31, 2024, Piramal Pharma Ltd's Interest Income Expense amounts to 1.1B INR.
What is Piramal Pharma Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
-10%
Over the last year, the Interest Income Expense growth was 80%. The average annual Interest Income Expense growth rates for Piramal Pharma Ltd have been -10% over the past three years .
You don't have any saved screeners yet